Jonathan J. Chang

Jonathan J. Chang

Auto-generated profile, based on publicly available information

Jonathan J. Chang

Wallace H. Coulter Department of Biomedical Engineering Georgia Institute of Technology and Emory University Atlanta GA 30332 USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Neoplasia
Verified
Journal Article
Open access
AHAnisha M. Hammer
Anisha M. Hammer
GSGina M. Sizemore
Gina M. Sizemore
VSVasudha C. Shukla
Vasudha C. Shukla
AAAlex Avendano
Alex Avendano
SSSteven T. Sizemore
Steven T. Sizemore
MOMichael C. Ostrowski
Michael C. Ostrowski
The extracellular matrix (ECM) is critical for mammary ductal development and differentiation, but how mammary fibroblasts regulate ECM remodeling remains to be elucidated. Herein, we used a mouse genetic model to activate platelet derived growth factor receptor-alpha (PDGFRα) specifically in the stroma. Hyperactivation of PDGFRα in the mammary stroma severely hindered pubertal mammary ductal morphogenesis, but did not interrupt the lobuloalveolar differentiation program. Increased stromal PDGFRα signaling induced mammary fat pad fibrosis with a corresponding increase in interstitial hyaluronic acid (HA) and collagen deposition. Mammary fibroblasts with PDGFRα hyperactivation also decreased hydraulic permeability of a collagen substrate in an in vitro microfluidic device assay, which was mitigated by inhibition of either PDGFRα or HA. Fibrosis seen in this model significantly increased the overall stiffness of the mammary gland as measured by atomic force microscopy. Further, mammary tumor cells injected orthotopically in the fat pads of mice with stromal activation of PDGFRα grew larger tumors compared to controls. Taken together, our data establish that aberrant stromal PDGFRα signaling disrupts ECM homeostasis during mammary gland development, resulting in increased mammary stiffness and increased potential for tumor growth.

26 October 2018 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
JPJason R Pitarresi
Jason R Pitarresi
XLXin Liu
Xin Liu
AAAlex Avendano
Alex Avendano
KTKatie A Thies
Katie A Thies
GSGina M Sizemore
Gina M Sizemore
MOMichael C Ostrowski
Michael C Ostrowski
The contribution of the tumor microenvironment to pancreatic ductal adenocarcinoma (PDAC) development is currently unclear. We therefore examined the consequences of disrupting paracrine Hedgehog (HH) signaling in PDAC stroma. Herein, we show that ablation of the key HH signaling geneSmoothened(Smo) in stromal fibroblasts led to increased proliferation of pancreatic tumor cells. Furthermore,Smodeletion resulted in proteasomal degradation of the tumor suppressor PTEN and activation of oncogenic protein kinase B (AKT) in fibroblasts. An unbiased proteomic screen identified RNF5 as a novel E3 ubiquitin ligase responsible for degradation of phosphatase and tensin homolog (PTEN) inSmo-null fibroblasts.Ring Finger Protein 5(Rnf5) knockdown or pharmacological inhibition of glycogen synthase kinase 3β (GSKβ), the kinase that marks PTEN for ubiquitination, rescued PTEN levels and reversed the oncogenic phenotype, identifying a new node of PTEN regulation. In PDAC patients, low stromal PTEN correlated with reduced overall survival. Mechanistically, PTEN loss decreased hydraulic permeability of the extracellular matrix, which was reversed by hyaluronidase treatment. These results define non-cell autonomous tumor-promoting mechanisms activated by disruption of the HH/PTEN axis and identifies new targets for restoring stromal tumor-suppressive functions.

1 October 2008 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
PAPhil B. Alper
Phil B. Alper
TMThomas H. Marsilje
Thomas H. Marsilje
DMDaniel Mutnick
Daniel Mutnick
WLWenshuo Lu
Wenshuo Lu
ACArnab Chatterjee
Arnab Chatterjee
STShin-Shay Tian
Shin-Shay Tian

22 November 2019 in APL Bioengineering
Verified
Journal Article
Open access
PDF file
HVHannah Viola
Hannah Viola
JCJonathan Chang
Jonathan Chang
JGJocelyn R. Grunwell
Jocelyn R. Grunwell
LHLouise Hecker
Louise Hecker
RTRabindra Tirouvanziam
Rabindra Tirouvanziam
STShuichi Takayama
Shuichi Takayama
Complex in vitro models of the tissue microenvironment, termed microphysiological systems, have enormous potential to transform the process of discovering drugs and disease mechanisms. Such a paradigm shift is urgently needed in acute respiratory distress syndrome (ARDS), an acute lung condition with no successful therapies and a 40% mortality rate. Here, we consider how microphysiological systems could improve understanding of biological mechanisms driving ARDS and ultimately improve the success of therapies in clinical trials. We first discuss how microphysiological systems could explain the biological mechanisms underlying the segregation of ARDS patients into two clinically distinct phenotypes. Then, we contend that ARDS-mimetic microphysiological systems should recapitulate three critical aspects of the distal airway microenvironment, namely, mechanical force, inflammation, and fibrosis, and we review models that incorporate each of these aspects. Finally, we recognize the substantial challenges associated with combining inflammation, fibrosis, and/or mechanical force in microphysiological systems. Nevertheless, complex in vitro models are a novel paradigm for studying ARDS, and they could ultimately improve patient care.

31 January 2025 in Advanced Healthcare Materials
Verified
Journal Article
Open access
JCJonathan J. Chang
Jonathan J. Chang
KBKelsey Brew
Kelsey Brew
JHJamie Aaron Golden Hamilton
Jamie Aaron Golden Hamilton
VKVarun Kumar
Varun Kumar
JDJosé A. Diaz
José A. Diaz
STShuichi Takayama
Shuichi Takayama
Vascular hypo‐fibrinolysis is a historically underappreciated and understudied aspect of venous thromboembolism (VTE). This paper describes the development of a micro‐clot dissolution assay for quantifying the fibrinolytic capacity of endothelial cells – a key driver of VTE development. This assay is enabled using aqueous two‐phase systems (ATPS) to bioprint microscale fibrin clots over human umbilical vein endothelial cells (HUVECs). Importantly, these micro‐clots are orders of magnitude smaller than conventional fibrin constructs and allow HUVEC‐produced plasminogen activators to mediate visually quantifiable fibrinolysis. Using live‐cell time‐lapse imaging, micro‐clot dissolution by HUVECs is tracked, and fibrinolysis kinetics are quantified. The sensitivity of cell‐driven fibrinolysis to various stimuli is rapidly tested. The physiological relevance of this convenient high‐throughput assay is illustrated through treatments with lipopolysaccharide (LPS) and rosuvastatin that elicit anti‐ and pro‐fibrinolytic responses, respectively. Furthermore, treatment with baricitinib, an anti‐inflammatory therapeutic found to increase cardiovascular risks after market approval, provokes an anti‐fibrinolytic response – which highlights the potential role of endothelial cells in increasing VTE risk for patients receiving this drug. This endothelial cell fibrinolysis assay provides a high‐throughput and versatile drug testing platform – potentially allowing for early preclinical identification of therapeutics that may beneficially enhance or adversely impair endothelial fibrinolysis.